PUR0200

May 10, 2017May 11, 2017

Pulmatrix Receives US Patent for PUR0200, an Inhaled Formulation for Lung Diseases

COPD, News

Pulmatrix has received a U.S. patent for PUR0200, an inhaled formulation of tiotropium bromide for lung diseases such as chronic obstructive pulmonary disease (COPD). The company said the powder it developed does a better ... Read more

July 25, 2016July 25, 2016

PUR0200, an Inhaled Bronchodilator for COPD, Shows Promise in Pilot Study

COPD, News

PUR0200, a new dry powder formulation being developed for the treatment of chronic obstructive pulmonary disease (COPD), has shown positive pharmacokinetic results in a Phase 1 pilot study. The results were ... Read more

February 23, 2016May 13, 2016

Capsugel and Pulmatrix Partnering to Develop Inhaled Therapeutics for Range of Lung Diseases

COPD, Cystic Fibrosis, Idiopathic Pulmonary Fibrosis, News

Capsugel and Pulmatrix, Inc., entered a partnership to advance the development and manufacture of inhaled therapeutics to treat serious pulmonary diseases, based on Pulmatrix’s iSPERSE technology. “This collaboration provides us with ... Read more

February 4, 2016May 12, 2016

European Clinical Trial Enrolling Patients for COPD Treatment

COPD, News

Pulmatrix Inc., a clinical stage biopharma dedicated to the development of inhaled therapies to address serious pulmonary diseases, recently announced that its European pilot bioequivalence study on PUR0200 for the ... Read more

September 24, 2015November 9, 2015

Pulmatrix To Report Phase IB Data For PUR0200 COPD Therapy At European Respiratory Society Congress

COPD, News

Pulmatrix, a biotechnology company developing inhalable formulations using its patented iSPERSE technology for patients affected by severe pulmonary abnormalities, recently announced that the company will be reporting key data from a phase IB clinical ... Read more

June 17, 2015November 9, 2015

Pulmatrix And Mylan Enter Enter Into Agreement To Develop PUR0200, iSPERSE COPD Therapies

COPD, News

Pulmatrix, a clinical stage bio-pharmaceutical firm advancing innovative therapies via inhalation to address serious pulmonary diseases, has recently announced it has entered into a partnership with Mylan N.V., which is a leading worldwide global pharmaceutical company. ... Read more